title: Bilateral subdural hemorrhage as a possible adverse event of gefitinib in a patient with non-small cell lung cancer.
abstract: Gefitinib, a selective inhibitor of epidermal growth factor receptor tyrosine kinase is an effective agent used in the treatment of patients with advanced non-small cell lung cancer (NSCLC). Adverse drug reactions were frequently observed in the skin, gastrointestinal tract, and liver, but they were generally mild in severity and reversible. Therefore, gefitinib has been regarded as a relatively safe agent. As a serious adverse effect, however, acute lung injury has been reported. The present report describes a patient with NSCLC who developed bilateral subdural hemorrhage as a possible adverse drug reaction after gefitinib therapy. We expect that this case may provide a reference for clinicians being involved in the treatment with gefitinib.
authors.affiliation: Department of Internal Medicine, Hallym Medical Center, Hallym University College of Medicine, Seoul, Republic of Korea. harricil@hotmail.com
authors.forename: Jung Han
authors.initials: JH
authors.lastname: Kim
authors.forename: Hyeong Su
authors.initials: HS
authors.lastname: Kim
authors.forename: Jong Soo
authors.initials: JS
authors.lastname: Choi
authors.forename: Kyung Min
authors.initials: KM
authors.lastname: Lee
authors.forename: Young Chul
authors.initials: YC
authors.lastname: Shin
authors.forename: Byung Moo
authors.initials: BM
authors.lastname: Ahn
authors.forename: Dae Ro
authors.initials: DR
authors.lastname: Choi
authors.forename: Jung Hye
authors.initials: JH
authors.lastname: Kwon
authors.forename: Sarah
authors.initials: S
authors.lastname: Park
authors.forename: Ho Young
authors.initials: HY
authors.lastname: Kim
authors.forename: Joo Young
authors.initials: JY
authors.lastname: Jung
authors.forename: Hyo Jung
authors.initials: HJ
authors.lastname: Kim
authors.forename: Hun Ho
authors.initials: HH
authors.lastname: Song
authors.forename: Dae Young
authors.initials: DY
authors.lastname: Zang
mesh_terms: D000368:Aged; D000970:Antineoplastic Agents / Q000009:adverse effects*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy*; D005260:Female; D000077156:Gefitinib; D006408:Hematoma, Subdural / Q000139:chemically induced* / Q000188:drug therapy; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy*; D011799:Quinazolines / Q000009:adverse effects*; D014057:Tomography, X-Ray Computed
chemical_list: D000970:Antineoplastic Agents; D011799:Quinazolines; D000077156:Gefitinib